FHA
SLNO

First Horizon Advisors’s Soleno Therapeutics SLNO Stock Holding History

First Horizon Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$670 Buy
+8
New +$599 ﹤0.01% 2230

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

First Horizon Advisors's SLNO Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Soleno Therapeutics (SLNO) in Q2 2025: 8 shares worth $670. The stake represents ﹤0.01% of the portfolio and ranks #2230 among its holdings.

233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • First Horizon Advisors held 8 shares of Soleno Therapeutics worth $670 as of Q2 2025.
  • Soleno Therapeutics was a new First Horizon Advisors position in Q2 2025.
  • Soleno Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #2230 holding.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.